-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

Benzinga·08/07/2026 12:09:39
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.